RobertIHaddadMD

Oncology • Boston, MA

Head & Neck Cancer

Division Chief /Head and Neck Oncology Dana Farber Cancer Institute Professor of Medicine, Harvard Medical School

Join to view full profile

Dr. Haddad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Haddad's full profile

Already have an account?

Office
450 Brookline Avenue
Dana Farber Cancer Institute
Boston, MA 02215
Phone+1 617-632-3090

Fax+1 617-632-4448
Is this information wrong?

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1998 - 2001
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1995 - 1998
St Joseph's University Medical SchoolClass of 1995

Certifications & Licensure

MA State Medical License 2001 - 2025
FL State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Boston Magazine Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2013

Clinical Trials

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Start of enrollment: 2004 Aug 01
Completed
Phase 3
Randomized Amifostine For SCCHN Start of enrollment: 2003 May 01
Completed
Phase 2
Title XELOX FOR SALIVARY GLAND CANCERS Start of enrollment: 2004 Oct 01
Terminated
Phase 2
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2007 Jan 01
Completed
Phase 1
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck Start of enrollment: 2007 Mar 01
Completed
Phase 2
A Randomized Phase III Trial Comparing Sequential Therapy With TPF/ Chemoradiation (ST) to Cisplatinum-Based Chemoradiotherapy With Accelerated Concomitant Boost Radiotherapy (CRT) For Locally Advanced Squamous Cell Cancer of the Head and Neck ("The Parad Start of enrollment: 2004 Aug 01
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study Start of enrollment: 2011 Jul 01
Terminated
Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers Start of enrollment: 2012 Sep 01
Unknown status
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Start of enrollment: 2014 May 29
Completed
Phase 3
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer Start of enrollment: 2019 Jun 11
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Revisiting TNM staging for EBV-related nasopharyngeal carcinoma.
Dennis, M., Haddad, R.> ;Cancer Cell. 2024 Mar 11
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design.
Robert L Ferris, Hisham Mehanna, Jonathan D Schoenfeld, Makoto Tahara, Sue S Yom, Robert Haddad, André König, Pauline Witzler, Marcis Bajars, Christophe Le Tourneau> ;Future Oncology. 2024 Apr 1
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck-Reply.
Kevin J Harrington, Robert Haddad> ;JAMA Oncology. 2024 Jan 1
2 citations
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
Glenn J Hanna, Alessandro Villa, Shuvro P Nandi, Ruichao Shi, Anne ONeill, Mofei Liu, Charles T Quinn, Nathaniel S Treister, Herve Y Sroussi, Piamkamon Vacharotayangul...> ;JAMA Oncology. 2024 Jan 1
Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles.
Yuanming Xu, Natalie Wen, Robert I Haddad, Stephen T Sonis, Alessandro Villa> ;The Oncologist. 2024 Mar 4
5 citations
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Oliveira, G., Egloff, A., Afeyan, A., Wolff, J., Zeng, Z., Chernock, R., Zhou, L., Messier, C., Lizotte, P., Pfaff, K., Stromhaug, K., Penter, L., Haddad, R., Hanna, G...> ;Science Immunology. 2023 Sep 8
7 citations
Development and Validation of an Automated Image-Based Deep Learning Platform for Sarcopenia Assessment in Head and Neck Cancer.
Zezhong Ye, Anurag Saraf, Yashwanth Ravipati, Frank Hoebers, Paul J Catalano, Yining Zha, Anna Zapaishchykova, Jirapat Likitlersuang, Christian Guthier, Roy B Tishler,...> ;JAMA Network Open. 2023 Aug 1
1 citations
β-catenin/CBP activation of mTORC1 signaling promotes partial epithelial-mesenchymal states in head and neck cancer.
Eric R Reed, Stacy A Jankowski, Anthony J Spinella, Vikki Noonan, Robert Haddad, Kenichi Nomoto, Junji Matsui, Manish V Bais, Xaralabos Varelas, Maria A Kukuruzinska, ...> ;Translational Research. 2023 Oct 1
Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
Robert I Haddad, Kevin Harrington, Makoto Tahara, Petr Szturz, Christophe Le Tourneau, Satu Salmio, Marcis Bajars, Nancy Y Lee> ;Cancer Treatment Reviews. 2023 Sep 1
3 citations
Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Robert Haddad, Rossella Elisei, Ana O Hoff, Zhiyan Liu, Fabian Pitoia, Giancarlo Pruneri, Peter M Sadow, Fernando Soares, Andrew Turk, Michelle D Williams, Lori J Wirt...> ;JAMA Oncology. 2023 Aug 1
10 citations
Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, rand...
Benjamin H Kann, Jirapat Likitlersuang, Dennis Bontempi, Zezhong Ye, Sanjay Aneja, Richard Bakst, Hillary R Kelly, Amy F Juliano, Sam Payabvash, Jeffrey P Guenette, Ra...> ;The Lancet. Digital Health. 2023 Jun 1
16 citations
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 ...
Kevin J Harrington, Robert L Ferris, Maura Gillison, Makoto Tahara, Athanasios Argiris, Jérôme Fayette, Michael Schenker, Åse Bratland, John W T Walker, Peter Grell, C...> ;JAMA Oncology. 2023 Jun 1
Fully-automated sarcopenia assessment in head and neck cancer: development and external validation of a deep learning pipeline.
Zezhong Ye, Anurag Saraf, Yashwanth Ravipati, Frank Hoebers, Yining Zha, Anna Zapaishchykova, Jirapat Likitlersuang, Roy B Tishler, Jonathan D Schoenfeld, Danielle N M...> ;Medrxiv. 2023 Mar 6
4 citations
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Sophie Wildsmith, Weimin Li, Song Wu, Ross Stewart, Nassim Morsli, Rajiv Raja, Qu Zhang, Jiabu Ye, Philip He, Jagdish Shetty, Alejandro Yovine, Nicholas Holoweckyj, Ka...> ;Clinical Cancer Research. 2023 Jun 1
4 citations
Diagnostic performance of computed tomography features in detecting oropharyngeal squamous cell carcinoma extranodal extension.
Ngoc-Anh Tran, Miklos Palotai, Glenn J Hanna, Jonathan D Schoenfeld, Camden P Bay, Eleni M Rettig, Paul M Bunch, Amy F Juliano, Hillary R Kelly, Chong Hyun Suh, David ...> ;European Radiology. 2023 May 1
29 citations
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KE...
A Psyrri, J Fayette, K Harrington, M Gillison, M-J Ahn, S Takahashi, J Weiss, J-P Machiels, S Baxi, A Vasilyev, A Karpenko, M Dvorkin, C-Y Hsieh, S C Thungappa, P P Se...> ;Annals of Oncology. 2023 Mar 1
8 citations
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
David G Pfister, Robert I Haddad, Francis P Worden, Jared Weiss, Ranee Mehra, Laura Q M Chow, Stephen V Liu, Hyunseok Kang, Nabil F Saba, Lori J Wirth, Ammar Sukari, E...> ;Cancer Medicine. 2023 Mar 1
24 citations
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of Ch...
Robert I Haddad, Kevin Harrington, Makoto Tahara, Robert L Ferris, Maura Gillison, Jerome Fayette, Amaury Daste, Piotr Koralewski, Bogdan Zurawski, Miren Taberna, Nabi...> ;Journal of Clinical Oncology. 2023 Apr 20
20 citations
Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer.
Eleni M Rettig, Annette A Wang, Ngoc-Anh Tran, Evan Carey, Tanujit Dey, Jonathan D Schoenfeld, Kartik Sehgal, Jeffrey P Guenette, Danielle N Margalit, Rosh Sethi, Ravi...> ;JAMA Otolaryngology-- Head & Neck Surgery. 2022 Dec 1
34 citations
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
Amin H Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W Akl, Pier Vitale Nuzzo, Tarek H Mouhieddine, Tomin Perea-Chamblee, Kodi Taraszka, Hab...> ;Cancer Cell. 2022 Oct 10
20 citations
Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
Douglas R Adkins, Robert I Haddad> ;Cancer Treatment Reviews. 2022 Sep 1
91 citations
Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
Adrienne M Luoma, Shengbao Suo, Yifan Wang, Lauren Gunasti, Caroline B M Porter, Nancy Nabilsi, Jenny Tadros, Andrew P Ferretti, Sida Liao, Cagan Gurer, Yu-Hui Chen, S...> ;Cell. 2022 Aug 4
17 citations
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study.
Z Bakouny, C Labaki, S Bhalla, A L Schmidt, J A Steinharter, J Cocco, D A Tremblay, M M Awad, A Kessler, R I Haddad, M Evans, F Busser, M Wotman, C R Curran, B S Zimme...> ;Annals of Oncology. 2022 Aug 1
Head and neck cancer: high-end technology is no guarantee of high-quality care - Authors' reply.
Nabil F Saba, Mayur D Mody, James W Rocco, Robert I Haddad, Sue S Yom> ;Lancet. 2022 Jun 4
2 citations
Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers.
Mona Arbab, Yu-Hui Chen, Roy B Tishler, Lauren Gunasti, Jason Glass, Jo Ann Fugazzotto, Joseph H Killoran, Rosh Sethi, Eleni Rettig, Donald Annino, Laura Goguen, Ravin...> ;Head & Neck. 2022 Jun 1
Join now to see all

Journal Articles

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
Glenn J Hanna, Nicole Chau, Jochen Lorch, Robert I Haddad, JAMA Oncology
Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature

Other

Human papillomavirus associated head and neck cancer
Haddad RI
http://www.uptodate.com/contents/human-papillomavirus-associated-head-and-neck-cancer
UpToDate, Wolters Kluwer Health - 2013-04-15

Authored Content

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaAugust 2020

Press Mentions

Study Identifies Predictors of Immunotherapy Response in Head and Neck CancerApril 12th, 2018
Immunovaccine Announces Dosing of First Patient in Investigator-Sponsored Phase 1b/2 Clinical Trial Evaluating Immuno-Oncology Candidate Targeting Incurable HPV-Related CancersApril 18th, 2017
Some Head and Neck Cancer Patients Benefit from Continued Checkpoint Inhibitor TreatmentApril 3rd, 2017
Join now to see all